Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02922777 | Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. | completed | Phase 1 | 23 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03643484 | IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy | completed | — | 634 | AstraZenecaINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04676009 | Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer Patients(ERICA) | completed | N/A | 26 | Centre Leon BerardOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04808050 | Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer(THASSOS-INTL) | completed | — | 748 | AstraZenecaINDUSTRY | 7 | Feb 21, 2024 | clinicaltrials |
| NCT04948411 | Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil | completed | — | 33 | Latin American Cooperative Oncology GroupOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03836469 | Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil(RELANCE) | completed | — | 403 | Latin American Cooperative Oncology GroupOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03892096 | Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer | completed | — | 130 | Cadex GenomicsINDUSTRY | 2 | Feb 7, 2024 | clinicaltrials |
| NCT04577638 | Accelerated Radio-Immunotherapy for Lung Cancer(AIRING) | completed | Phase 2 | 8 | Center Eugene MarquisOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT01542437 | Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 66 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04046614 | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology(NintNivo) | completed | Phase 1 / Phase 2 | 56 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02789345 | A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer | completed | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 5 | Feb 5, 2024 | clinicaltrials |
| NCT02073968 | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer(PAINT) | completed | Phase 2 | 35 | Albert Einstein College of MedicineOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02567799 | BIO 300 Non-Small Cell Lung Cancer Study(NSCLC) | completed | Phase 1 / Phase 2 | 21 | Humanetics CorporationINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT03446417 | A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer | completed | Phase 1 | 34 | Zeno Pharmaceuticals, Inc.INDUSTRY | 2 | Jan 25, 2024 | clinicaltrials |
| NCT06224504 | Clinical Effectiveness of Combining Mindfulness-Based Stress Reduction With Exercise Interventione | completed | N/A | 60 | Shanxi Bethune HospitalOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT04654234 | Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Induction Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiotherapy | completed | — | 15 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02163733 | Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 | 38 | AstraZenecaINDUSTRY | 4 | Jan 22, 2024 | clinicaltrials |
| NCT03087760 | Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer | completed | Phase 2 | 32 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04816981 | AI-EBUS-Elastography for LN Staging(AI-EBUS-E) | completed | N/A | 100 | St. Joseph's Healthcare HamiltonOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT01459497 | Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer | completed | Phase 3 | 103 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03083691 | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | completed | Phase 2 | 90 | Lung Cancer Group CologneOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04189679 | Identification of a Predictive Metabolic Signature of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Carcinoma(METABO-ICI) | completed | — | 62 | University Hospital, GrenobleOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT06209229 | Role of Neutrophils and Electro-bioluminescence in the Rehabilitation(RNE) | completed | Phase 1 | 34 | MIPO ClinicOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04552613 | Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients | completed | N/A | 114 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT01383135 | Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 | completed | Early Phase 1 | 27 | Stanford UniversityOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04620330 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer(RAMP202) | completed | Phase 2 | 90 | Verastem, Inc.INDUSTRY | 5 | Jan 12, 2024 | clinicaltrials |
| NCT04803305 | Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia | completed | Phase 1 | 18 | PfizerINDUSTRY | 2 | Jan 12, 2024 | clinicaltrials |
| NCT01763645 | A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 3 | 353 | BiocadINDUSTRY | 4 | Jan 11, 2024 | clinicaltrials |
| NCT02581943 | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | completed | Phase 2 | 43 | Wake Forest University Health SciencesOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05273827 | Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium | completed | — | 81 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05318443 | A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 512 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05450081 | Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients | completed | — | 140 | Hunan Province Tumor HospitalOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04271384 | Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer | completed | Phase 2 | 25 | Hospital Israelita Albert EinsteinOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT02482168 | Study of the CD40 Agonistic Monoclonal Antibody APX005M | completed | Phase 1 | 43 | Apexigen America, Inc.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT03845270 | Her2-positive Lung Cancer Treated With Dedicated Drug(R2D2) | completed | Phase 2 | 46 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT04311034 | A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 37 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT00641238 | Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA) | completed | — | 20 | State University of New York - Upstate Medical UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03736993 | Metabolomics Predict Therapy Response(PROLUNG) | completed | N/A | 160 | Hasselt UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT04299048 | Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. | completed | Phase 1 | 11 | PfizerINDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03014648 | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 28 | Liza Villaruz, MDOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06161935 | A Study of Lymph Node Metastatic Pattern Based Incorporating Tumor Location, GGO Components and Size for Non-small Cell Lung Cancer | completed | — | 7,067 | Fudan UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT06168916 | AIMN Multicenter Study: 18 F-FDG PET-CT With or Without Contrast Medium in the Staging and Radiation of Lung Cancer? | completed | — | 14 | IRCCS San RaffaeleOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | completed | Phase 2 | 27 | Joel NealOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02716038 | Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | completed | Phase 2 | 39 | Columbia UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Feb 21, 2024source: clinicaltrials